+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Global Acromegaly Drug Pipeline Trends 2019: Discovery, Pre-clinical, Clinical, In Approval Therapeutics, Companies and Markets

  • ID: 4830044
  • Drug Pipelines
  • August 2019
  • Region: Global
  • 78 pages
  • VPA Research
1 of 3

FEATURED COMPANIES

  • Amryt Pharma plc
  • Camurus AB
  • Chiasma Inc
  • DexTech Medical AB
  • Enesi Pharma Ltd
  • GlyTech Inc
  • MORE
High levels of pipeline activity are being observed in Acromegaly treatment during 2019. Clinical development activities are being undertaken by more than 15 companies including Amryt Pharma plc, Antisense Therapeutics Ltd, Aquestive Therapeutics Inc, Auritec Pharmaceuticals Inc, Camurus AB and others.

A Significant contribution to the Acromegaly pipeline is being observed from emerging companies opting for new approaches to clinical development strategy. The early stage and late-stage Acromegaly pipeline included 18 compounds, driven by increasing number of targeted therapies. Progress is being made in accelerating compounds into advanced stages. However, fluctuating trends are being observed in average duration across three phases.

Increased understanding of underlying causes of Acromegaly condition and increased access to investments is encouraging growth of Acromegaly drug pipeline. However, despite high levels of pipeline activity, increasing clinical trial costs and decreasing drug approval rates is requiring companies to focus more on understanding clinical development pipeline compounds.

The research study is structured to provide clear and actionable insights into Acromegaly drug pipeline for companies to optimize spending levels by understanding competition, their pipeline products and prospect of further advances over the next few years.

The report addresses the discovery, research and pre-clinical stage active Acromegaly therapeutic candidates. Further, drugs in clinical stage including phase 1, phase 2, phase 3 and pre-registration phases are also analyzed.

The current report examines the current Acromegaly pipeline along with current development status, regulatory progress, mechanism of action, route of administration, collaborating companies, sponsors, molecule type, and research/discovery details.

In addition to drug overview, recent developments, the report also provides mechanism of action, Pre-clinical trial details and Clinical trial details for each of the drug candidates of Acromegaly . Further, orphan drug status, fast track designation, grants awarded and other special status for Acromegaly pipeline compounds are also included.

This study was produced independently by the publisher from their proprietary databases, primarily to assist users to develop in-depth understanding of 2019 Acromegaly pipeline and formulate effective research and development strategies.

Research Methodology

Our integrated data reports are built through robust research methodology to ensure our users can build on the insights and data accuracy for their expansion plans. Both primary and secondary research methods are used with stringent quality checks at each stage to evaluate trends, analysis and forecasts.

Scope of the Research

Acromegaly Pipeline candidates
  • Pre-clinical Phase: Discovery, research, pre-clinical
  • Early Phase: Phase 1 and Phase 2 Acromegaly drugs
  • Late phase: Phase 3 and in-approval Acromegaly drugs
Companies involved in the Pipeline
  • Company overview
  • Snapshot
  • Acromegaly therapeutic treatment activities
Details for each Acromegaly drug candidate
  • Snapshot
  • Drug Name
  • Alternative Names
  • Company
  • Originator
  • Phase
  • Molecule Type
  • Orphan Drug Status
  • Drug Overview
  • Mechanism of Action
  • Current Status
  • Trial Details
Other details
  • Pre-clinical trials for each drug candidate
  • Clinical trials for each drug candidate
Recent Acromegaly therapeutic candidates, clinical trials, investments, grants, partnerships, licenses, awards and other news
Note: Product cover images may vary from those shown
2 of 3

FEATURED COMPANIES

  • Amryt Pharma plc
  • Camurus AB
  • Chiasma Inc
  • DexTech Medical AB
  • Enesi Pharma Ltd
  • GlyTech Inc
  • MORE
1.1 List of Tables
1.2 List of Figures

2 Executive Summary
2.1 Acromegaly - Disease Overview
2.2 Acromegaly - Pipeline Snapshot
2.3 Acromegaly - Pipeline Drugs by Phase
2.4 Acromegaly - Pipeline Drugs by Company
2.5 Acromegaly - Pipeline Drugs by Mechanism of Action

3 Company wise Pipeline Analysis
3.1 Amryt Pharma plc Acromegaly Drug Pipeline, H2- 2019
3.2 Antisense Therapeutics Ltd Acromegaly Drug Pipeline, H2- 2019
3.3 Aquestive Therapeutics Inc Acromegaly Drug Pipeline, H2- 2019
3.4 Auritec Pharmaceuticals Inc Acromegaly Drug Pipeline, H2- 2019
3.5 Camurus AB Acromegaly Drug Pipeline, H2- 2019
3.6 Chiasma Inc Acromegaly Drug Pipeline, H2- 2019
3.7 Crinetics Pharmaceuticals Inc Acromegaly Drug Pipeline, H2- 2019
3.8 Dauntless Pharmaceuticals Inc Acromegaly Drug Pipeline, H2- 2019
3.9 DexTech Medical AB Acromegaly Drug Pipeline, H2- 2019
3.10 Enesi Pharma Ltd Acromegaly Drug Pipeline, H2- 2019
3.11 Foresee Pharmaceuticals Co Ltd Acromegaly Drug Pipeline, H2- 2019
3.12 GeneScience Pharmaceuticals Co Ltd Acromegaly Drug Pipeline, H2- 2019
3.13 GlyTech Inc Acromegaly Drug Pipeline, H2- 2019
3.14 Ionis Pharmaceuticals Inc Acromegaly Drug Pipeline, H2- 2019
3.15 Italfarmaco SpA Acromegaly Drug Pipeline, H2- 2019
3.16 Midatech Pharma Plc Acromegaly Drug Pipeline, H2- 2019
3.17 Ono Pharmaceutical Co Ltd Acromegaly Drug Pipeline, H2- 2019
3.18 Strongbridge Biopharma plc Acromegaly Drug Pipeline, H2- 2019

4 Phase 1 Pipeline Drug Details
4.1 Acromegaly - Phase 1 Drug Details
4.2 Acromegaly - Phase 1 Drug Overview
4.3 Acromegaly - Phase 1 Mechanism of Action
4.4 Current Status
4.5 Trial Details

5 Phase 2 Pipeline Drug Details
5.1 Acromegaly - Phase 2 Drug Details
5.2 Acromegaly - Phase 2 Drug Overview
5.3 Acromegaly - Phase 2 Mechanism of Action
5.4 Current Status
5.5 Trial Details

6 Phase 3 Pipeline Drug Details
6.1 Acromegaly - Phase 3 Drug Details
6.2 Acromegaly - Phase 3 Drug Overview
6.3 Acromegaly - Phase 3 Drug Mechanism of Action
6.4 Current Status
6.5 Trial Details

7 Pre-clinical Phase Pipeline Drug Details
7.1 Acromegaly - Pre-clinical Phase Drug Details
7.2 Acromegaly - Pre-clinical Phase Drug Overview
7.3 Acromegaly - Pre-clinical Phase Drug Mechanism of Action
7.4 Current Status
7.5 Trial Details

8 Recent News and Developments

9 Appendix
9.1 About the Publisher
9.2 Sources and Research Methodology
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
  • Amryt Pharma plc
  • Antisense Therapeutics Ltd
  • Aquestive Therapeutics Inc
  • Auritec Pharmaceuticals Inc
  • Camurus AB
  • Chiasma Inc
  • Crinetics Pharmaceuticals Inc
  • Dauntless Pharmaceuticals Inc
  • DexTech Medical AB
  • Enesi Pharma Ltd
  • Foresee Pharmaceuticals Co Ltd
  • GeneScience Pharmaceuticals Co Ltd
  • GlyTech Inc
  • Ionis Pharmaceuticals Inc
  • Italfarmaco SpA
  • Midatech Pharma Plc
  • Ono Pharmaceutical Co Ltd
  • Strongbridge Biopharma plc
Note: Product cover images may vary from those shown
Adroll
adroll